TY - JOUR
KW - Amoxicillin
KW - Amoxicillin-Potassium Clavulanate Combination
KW - Ampicillin
KW - Animals
KW - Anti-Bacterial Agents
KW - Clavulanic Acids
KW - Drug Therapy, Combination
KW - Mice
KW - Microbial Sensitivity Tests
KW - Mycobacterium
KW - Penicillanic Acid
KW - Piperacillin
KW - Piperacillin, Tazobactam Drug Combination
KW - Sulbactam
KW - beta-Lactamase Inhibitors
AU - Prabhakaran K
AU - Harris E B
AU - Randhawa B
AU - Adams L B
AU - Williams D L
AU - Hastings R C
AB - <p>Mycobacterium tuberculosis and Mycobacterium leprae develop resistance against the drugs used to treat tuberculosis and leprosy, respectively. Now multidrug-resistant tuberculosis is spreading in many countries, especially with the emergence of AIDS. Multidrug treatment is being promoted at present to eradicate leprosy. Since M. leprae may also become multidrug-resistant, new approaches have to be adopted for controlling mycobacterial diseases. Mycobacteria usually synthesize beta-lactamase and are insensitive to beta-lactam antibiotics. M. tuberculosis contains a constitutive beta-lactamase; de-repression of beta-lactamase has been reported in M. leprae. Three different beta-lactam/beta-lactamase-inhibitor combinations (ampicillin/sulbactam, amoxicillin/clavulanate and piperacillin/tazobactam) were used to suppress the growth of several strains of mycobacteria (including M. tuberculosis H37Rv) in vitro. Ampicillin/sulbactam is a potent bactericidal agent against M. leprae multiplying in mouse foot pads. In the present work, ampicillin/sulbactam showed higher activity than the other drug combinations. The beta-lactam/beta-lactamase inhibitors are likely to be effective as rational therapeutic agents against mycobacterial infections.</p>
BT - Microbios
C1 - http://www.ncbi.nlm.nih.gov/pubmed/8302203?dopt=Abstract
DA - 1993
IS - 309
J2 - Microbios
LA - eng
N2 - <p>Mycobacterium tuberculosis and Mycobacterium leprae develop resistance against the drugs used to treat tuberculosis and leprosy, respectively. Now multidrug-resistant tuberculosis is spreading in many countries, especially with the emergence of AIDS. Multidrug treatment is being promoted at present to eradicate leprosy. Since M. leprae may also become multidrug-resistant, new approaches have to be adopted for controlling mycobacterial diseases. Mycobacteria usually synthesize beta-lactamase and are insensitive to beta-lactam antibiotics. M. tuberculosis contains a constitutive beta-lactamase; de-repression of beta-lactamase has been reported in M. leprae. Three different beta-lactam/beta-lactamase-inhibitor combinations (ampicillin/sulbactam, amoxicillin/clavulanate and piperacillin/tazobactam) were used to suppress the growth of several strains of mycobacteria (including M. tuberculosis H37Rv) in vitro. Ampicillin/sulbactam is a potent bactericidal agent against M. leprae multiplying in mouse foot pads. In the present work, ampicillin/sulbactam showed higher activity than the other drug combinations. The beta-lactam/beta-lactamase inhibitors are likely to be effective as rational therapeutic agents against mycobacterial infections.</p>
PY - 1993
SP - 251
EP - 61
T2 - Microbios
TI - Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
VL - 76
SN - 0026-2633
ER -